Oncology Data Advisor™ · Updates in Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas. Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2019).Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall sur...

Selinexor (Xpovio®, Karyopharm Therapeutics) was recently FDA approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This approval extends to patients with DLBCL that resulted from follicular lymphoma and those who had previously received at least two prior lines of systemic therapy. John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine, discussed with i3 Health the importance of this approval and the fu...